HEPTANOIN, TRI-

Glucose Metabolism Disorders

University of Texas Southwestern Medical CenterSmall moleculePhase 2Dormant

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 95/ 100

Competitive context

9 Active assets in the Glucose Metabolism Disorders cohort.

Asset / Sponsor	Phase	Rating
Metformin SINA Health Education and Welfare Trust	Phase 4	BBB
ZIDOVUDINE Kirby Institute	Phase 4	BB
Empagliflozin SINA Health Education and Welfare Trust	Phase 4	BB
Exenatide RenJi Hospital	Phase 4	BB
Glargine Federico II University	Phase 4	BB

View all 28 →

Same molecule, other indications

HEPTANOIN, TRI- is also rated in:

GLUT1 deficiency syndromeDormant

BB

Indicative ·

69 / 100

Glucose Transporter Protein Type 1 Deficiency SyndromeDormant

BB

Indicative ·

69 / 100

encephalopathy due to GLUT1 deficiencyDormant

BB

Indicative ·

64 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.